First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease

Introduction: The effect of local ablative therapy (LAT) for oligoprogressive epidermal growth factor receptor (EGFR) mutation non-small cell lung cancer (NSCLC) remains undetermined. This study aimed to investigate the survival benefit of addition of LAT to EGFR-TKIs in EGFR-mutant NSCLC patients w...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Cancer
Egile Nagusiak: Xu, Qinghua, Liu, Hui, Meng, Shuyan, Jiang, Tao, Li, Xuefei, Liang, Shixiong, Ren, Shengxiang, Zhou, Caicun
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Ivyspring International Publisher 2019
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6360299/
https://ncbi.nlm.nih.gov/pubmed/30719148
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.26494
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak